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Abstract 
Kahalalide compounds are peptides that are isolated from a Hawaiian herbivorous marine species of mollusc, 
Elysia rufescens, and its diet, the green alga Bryopsis sp. Kahalalide F and its synthetic analogues are the 
most promising compounds of the Kahalalide family because they show anti-tumoral activity. Linear solid-
phase syntheses of Kahalalide F have been reported. Here we describe several new improved synthetic routes 
based on convergent approaches with distinct orthogonal protection schemes for the preparation of 
Kahaladide analogues. These strategies allow a better control and characterization of the intermediates 
because more reactions are performed in solution. Five derivatives of Kahalalide F were synthesized using 
several convergent approaches. 
KEYWORDS. Anti-tumoral compounds, Cyclic peptides, Desipeptides, Didehydroamino acids, Marine 
origin products, Natural products, Orthogonal protecting groups, Solid-phase synthesis,  
Introduction 
Kahalalide compounds are peptides that are isolated from a Hawaiian herbivorous marine species of mollusc, 
Elysia rufescens and its diet, the green alga Bryopsis sp.  Kahalalide F1 and analogues are the most promising 
compounds of the Kahalalide family because of their anti-tumoral activities.2  Thus, Kahalalide F alters the 
function of the lysosomal membrane, a characteristic that distinguishes it from all other known anti-tumour 
agents. This compound also inhibits TGF-alpha expression, blocks intracellular signalling pathways 
downstream of EGF and ErbB2 receptor family and induces non-p53-mediated apoptosis.3  Recent studies 
demonstrate that Kahalalide F induces cell necrosis in vivo (oncosis) and shows selectivity for tumour 
compared with healthy cells in vitro.4  Its activity is independent of multi-drug resistance (MDR) expression.5 
Kahalalide F is currently undergoing Phase II clinical trials in various solid tumours: melanoma, non-small 
cell lung cancer, and hepatocellular carcinoma. A Phase II trial for the treatment of patients with severe 
psoriasis is also ongoing.6 
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Members of the Kahalalide F family, which are head-to-side chain cyclodepsipeptides, have a complex 
structure, comprising six amino acids, among these the Z-didehydro-α-aminobutyric acid (ZDhb) (formed 
from dehydratation of a Thr residue), as a cyclic part between the carboxylic acid of a L-Val 1 and the 
secondary alcohol of the DaThr 6, and an exocyclic chain of seven amino acids with a terminal aliphatic/fatty 
acid group (R) (Figure 1).1,7,8,9 Compounds in which R is a methylhexanoic acid are of greatest interest. 10 
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Figure 1.  Structure of Kahalalide F. 
 
Linear solid-phase syntheses of Kahalalides involving cyclization and final deprotection performed in 
solution have been described.8,11 However, synthetic routes for Kahalalide compounds are still required. Here 
we report several new convergent strategies for the synthesis of Kahalalide F derivatives. Convergent 
strategies are defined as those in which peptide fragments are coupled to give the desired target 
molecule.12,13,14,15 The condensation of peptide fragments should lead to fewer problems in the isolation and 
purification of intermediates. The difference between the condensation product desired and the segments 
themselves, in terms of molecular size and chemical nature, should be sufficiently pronounced so as to permit 
their separation relatively easily. Several orthogonal protecting schemes have been used in these strategies.16   
Although solid-phase strategies are crucial for peptide synthesis,12b,17, 18,19,20 the method of choice for a 
convergent strategy involves a combination of solid-phase and solution chemistries.  Thus, protected peptides 
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are prepared in solid-phase and then combined in solution.21,22 a Paradigm of this strategy is the large-scale 
commercial production of enfuvitide (T-20 or Fuzeon), a 36-amino acid peptide.23  
Results and Discussion 
To render Kahalalide F a 14-building block peptide [13 amino acids and the methylhexanoic acid], the 
most convenient synthetic strategy involves dividing the peptide in two fragments, the N-terminal and the 
fragment containing the cycle.  Fragment composition can be modified in order to optimize condensation 
yields and minimize side reactions, such as epimerization.  
 
MeHex-AAA-OH
EEE
-CCC-DDDH-BBB MeHex-AAA
EEE
-CCC-DDD-BBB
C-Component N-Component KF
 
Scheme 1. Convergent strategy for the synthesis of Kahalalide F analogues. AAA, 
BBB, CCC, DDD, and EEE are amino acid residues. 
 
The preparation of the N-Component requires cyclization in solution and therefore the N-protection should 
also be kept during the cleavage of the lineal fragment from the resin. 
Solid-phase synthesis of protected peptides requires a resin that facilitates the release of the peptide without 
removing the side-chain protecting groups, which are removed as the last step of the synthesis.12a,13,14  In this 
regard, the tBu-based protecting groups are highly convenient because they are removed with high 
concentrations of trifluoroacetic acid (TFA) in the presence of scavengers and are stable to piperidine, used to 
remove the α-amino protecting group, and to low concentrations of TFA.  The super-acid-labile chlorotrityl 
chloride polystyrene (CTC, Barlos, ) resin allows the release of peptides with 1-2 % of TFA in 
CH2Cl2 or even with trifluoroethanol or hexafluoroacetone solutions.24  An additional advantage of the CTC 
resin is that its hindered structure minimizes the formation of the diketopiperazines (DKP) during removal of 
the temporal protecting group of the second amino acid.25,26  
General Strategies: Three sets of fragments were prepared.  Schemes 2 and 3 show the C-Components and 
their complementary N-Components synthesized. 
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MeHex−D-Val−L-Thr(tBu)−L-Val−D-Val−D-Pro−OH
MeHex−D-Val−L-Thr(tBu)−L-Val−D-Val−D-Pro−L-Orn(Boc)−OH
MeHex−D-Val−L-Thr(tBu)−L-Val−D-Val−D-Pro−L-Orn(Boc)−D-allo-Ile−OH
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C-Component 2:
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                 Scheme 2.  C-Components synthesized 
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Scheme 3.  N-Components synthesized 
A priori, the main advantage of strategy 1 is that the hardly racemizable Pro is the C-terminal amino acid 
for the C-Component. In contrast, the advantage of strategies 2 and 3 is that the N-Component does not 
contain any side-chain protecting group and therefore a level of protecting groups can be avoided for these 
fragments.   
All fragments were synthesized on the CTC-resin, starting with a limited incorporation of the first 9-
fluorenylmethoxycarbonyl (Fmoc)-amino acid in the presence of N,N-diisopropylethylamine (DIEA).27  The 
remaining resin chloride functions were capped with methanol (MeOH) to prevent the formation of tertiary 
amines after treatment with the piperidine used to remove the Fmoc group.28  The Fmoc-protecting group was 
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removed with piperidine−N,N-dimethylformamide (DMF) (1:4) and the peptide chain was elongated with 
N,N’-diisopropylcarbodiimide (DIPCDI) and 1-hydroxybenzotriazole (HOBt) as coupling reagents. Finally, 
the peptides were cleaved from the resin with TFA−CH2Cl2 (1:99), characterized by HPLC and ESMS, and 
purified by semi-preparative HPLC when necessary.   
Synthesis of the N-Components: The ZDhb moiety was incorporated through the dipeptide 
allyloxycarbonyl (Alloc)-Phe-ZDhb-OH, wich is much faster than incorporating sequentially Thr and Phe and 
performing the dehydratation of Thr to ZDhb on solid phase. 8,11 
Four synthetic strategies were used to prepare the three distinct N-Components (Scheme 4). All the strategies 
are based on the solid-phase synthesis of a branched peptide using a tri- or tetra-orthogonal protecting scheme 
and subsequent cyclization and deprotection of the N-terminal function in solution. Strategy 1, which 
produces the N-Component 1, follows the procedure previously described8,11 and starts with the incorporation 
of Fmoc-D-Val-OH on the CTC resin, followed by elongation until the D-aIle7, esterification of the β-
hydroxyl of the DaThr with Alloc-Val-OH.  The incorporation of protected Orn(Boc) residue on the main 
chain is then followed by the incorporation of the Alloc-Phe-ZDhb-OH on the branched one.  Strategy 3, 
which leads to the N-Component 2, is similar to 1, but elongation is stopped after incorporation of DaIle7.  In 
strategies 2 and 4, which yield N-Component 1and N-Component 3 respectively, synthesis starts with the 
incorporation of the Alloc-Phe-ZDhb-OH onto the CTC resin (see below for the discussion of the strategy).  
This study addressed: (i) the most convenient strategy in terms of coupling yield and racemization of the C-
terminal amino acid of the C-Component (strategies 1 or 2 vs. 3 and 4); (ii) for strategies 1 and 2 (N-
Component 1), the best semi-permanent protecting group [Fmoc, p-nitrobenzyloxycarbonyl (pNZ)11,29,30 in 
strategy 1 and Alloc in the 2]31 for the Nα-amino of Orn, taking into account that the t-butoxycarbonyl (Boc) 
group is reserved as permanent protecting group for the Nε-amino of the same Orn; and (iii) whether the 
dipeptide Alloc-Phe-ZDhb-OH is a good starting point for the elongation of the peptidic chain (strategies 2 
and 4) when compared with the traditional Fmoc-D-Val-OH4.     
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Scheme 4.  Strategies for the syntheses of the cyclic fragment.  
As protecting group for the Nα-amino of Orn, Fmoc, Alloc, and the recently described pNZ11,29,30 was 
examined (Scheme 4, strategies 1 and 2) as well as Boc (Scheme 4, strategies 3 and 4).  Alloc was removed 
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by Pd(0) in rather neutral conditions in the presence of a scavenger of the allyl carbocations.32  pNZ is 
orthogonal to the most common solid-phase peptide synthesis (SPPS) protecting groups such as t-butyl 
(tBu)/Boc, Fmoc, and Alloc.  It was removed under simple and practical neutral conditions by SnCl2 in the 
presence of catalytic amounts of acid.29  When the Fmoc group (strategy 1) was removed under the classical 
conditions piperidine−DMF (1:4), the major product was the linear peptide, which formed by aminolysis of 
the ester bond.33  However, the use of  diethylamine (DEA) (30 eq of DEA for 90 min at 25 ºC) minimized 
the undesired side-reaction.  In this case, although no opening of the cycle was detected, some starting 
product (around 5%)* remained in the reaction crude.  In the same strategy, the use of  pNZ-Orn(Boc)-OH 
instead of Fmoc-Orn(Boc)-OH was examined.   The ester bond was stable to the SnCl2 treatment used to 
remove pNZ.   
Furthermore, the same stability was achieved when the Alloc group (Scheme 4, strategy 2) was removed 
with Pd(0) in the presence of triethylsilane (TES).  To use Alloc as a semi-permanent protecting group, the 
classical strategy 1 used for the synthesis of Kahalalide F could not be followed because it would have been 
necessary to remove Alloc as Nα-protecting group of the Phe in the presence of the semi-permanent 
protecting group of the Orn (Scheme 4, Strategy 1).  Thus, a new strategy to circumvent this problem was 
assayed.  This strategy began with the incorporation of Alloc-Phe-ZDhb-OH as the first building block to the 
CTC resin using the same conditions required for the introduction of protected amino acids (Scheme 4, 
Strategy 2). The peptide chain was elongated using Fmoc for the α-amino protection of DVal, DaIle, DaThr, 
and DaIle, and Alloc** for the Orn(Boc).  This new strategy worked well in terms of cyclization yield and in 
addition showed two key advantages. Due to the defect of first protected building block required for the 
incorporation onto the CTC resin, a smaller amount of the precious Alloc-Phe-ZDhb-OH  was required 
compared with strategy 1, in which the dipeptide was introduced in excess.  Secondly and more importantly, 
                                                 
*
 The starting peptide contains a Fmoc group, which makes a difference in the ε of both compounds and 
therefore difficults the yield calculation.   
**
 In this strategy the Orn(Boc) could be also introduced as pNZ-Orn(Boc)-OH. 
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ZDhb does not show chirality and therefore no epimerization occurred during the cyclization step, which is 
the most prone for inducing racemization.  
In strategies 3 and 4, and as the N-Components 2 and 3 did not contain any side-chain protecting group, the 
Boc group was used as Nα-amino protecting group of the N-terminal residue (DaIle7 in strategy 3 and DaThr 
in the 4).  In addition to the full stability of the lactone bond to the conditions (TFA) used to remove that 
protecting group, the main advantages associated with the use of the Boc group were that the reagent to 
remove this group as well as the side-products formed were volatile and therefore could be removed by 
simple evaporation.   
Condensation of linear and cyclic fragments: First of all, and using C- and N-Components as models, we 
screened the coupling methods [DIPCDI/7-aza-1-hydroxybenzotriazole (HOAt) (1.5 eq. each);  1-ethyl-3-(3’-
dimethylaminopropyl)carbodiimide hydrochloride (EDC)/HOBt (3 eq. each); EDC/HOBt/N,N-
dimethylaminopyridine (DMAP) (4 eq., 4eq., 0.4 eq.); (7-azabenzotriazol-1-yloxy)-
tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP)/DIEA (1 eq., 3 eq.) +  PyAOP (1 eq after 1h), 
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo-[4,5-b]pyridinium hexafluorophosphate 3-oxide 
(HATU)/DIEA (1 eq., 3 eq.)] .  On the basis of this screening, we concluded that the method based on 
PyAOP gave the best results in terms of yields and the absence of side-products in the HPLC chromatograms 
(Table 1).   Phosphonium derivatives such as PyAOP are more convenient for slow couplings compared with 
aminium/uronium reagents such as HATU, since the latter can terminate the peptide chain through a 
guanidination reaction.34 Furthermore, PyAOP contains HOAt, which is the most reactive benzotriazole.35  
Each linear C-Component was then condensed with its corresponding N-Component in solution phase 
using PyAOP and DIEA.  The three protected peptides obtained were treated with TFA−H2O (9:1)  to remove 
the Boc and tBu groups and yielded Kahalalide F. 
A range of results were obtained depending on which C- and N-terminal amino acids of the C- and N-
Components, respectively, were involved.  From the point of view of the purity of the final product, the 
strategies that involved the concourse of C- and N-Components 1 and 2 were superior to that corresponding 
to fragments 3.   This can be explained because the latter involves coupling between two hindered β-branched 
 10
amino acids (DaIle and DaThr).  Furthermore, DaThr is part of the cycle, which may also impair the coupling 
of the protected peptide.   The C- and N-Component 1 strategy also gave slightly superior results. 
Conditions % of final product in the HPLC 
DIPCDI/HOAt (1.5 eq, 1.5 eq) 47 % (t= 48 h) 
EDC/HOBt/DMAP (4 eq, 4 eq, 
 0.4 eq) 
16 % (t= 6h), 
23 % (t=20h) 
PyAOP/DIEA (1eq, 3 eq) 
+ 1 eq PyAOP at t=  h 
35 % (t= 30 min) 
 54 % (t= overnight) 
HATU/DIEA (1eq, 3 eq)  + 1 eq 
PyAOP at t= 3 h 
43 %  (t= 30 min) 
49% (t=overnight) 
EDC/HOBt (3 eq, 3 eq) 5.8% (t= 30 min) 
53% (t= overnight) 
 
Table 1.  Srceening of C and N Components coupling methods.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  HPLC analysis of the solution coupling between C- and N-Components 1 over time.  
Linear gradient of MeCN (+0.036% TFA) into H2O (+0.045% TFA), from 30% to 100% in 15 min.  
 
Furthermore, when the C-terminal amino acids of the C-Component were Orn [C-Component 2 and N-
Component 2 (Strategy 3, Scheme 4)] or DaIle [C-Component 3 and N-Component 3 (Strategy 4, Scheme 4)], 
 
 
C-Fragment N-Fragment
Protected Kahalalide F
t = 0
t = 30 min
t = 1 h 30 min
t = 3 h 30 min
t = 5 h 30 min
t = overnight
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epimerisation of these amino acids was observed [4 % for the case of Orn (Figure 3) and more than 10% for 
DaIle (data no shown)].36 However, when the C-terminal amino acid of the linear fragment was D-Pro [C- 
and N-Components 1 (Strategy 1 or 2, Scheme 4)], epimerisation was not observed (Figure 4).  These results 
were obtained by comparing the HPLC crudes of the Kahalalide F compounds synthesized by the strategies 
and the three epimers, which were also synthesized by a stepwise strategy (substitution of DPro for LPro, of 
LOrn for DOrn, and of DaIle for Ile).  Our observations confirm that, due to its cyclic secondary amino 
function, Pro is less prone to racemize during fragment coupling. 
 
 
 
 
 
 
 
 
 
Figure 3.  HPLC analysis of the Boc protected Kahalalide F prepared from C- and N-Components 2 
(up and red) compared with the (DOrn8)-Kahalalide F (down and blue).  Linear gradient of MeCN 
(+0.036% TFA) into H2O (+0.045% TFA), from 30% to 100% in 15 min.   
 
 
 
 
 
 
 
 
Figure 4.  HPLC analysis of the Boc protected Kahalalide F prepared from C- and N-
Components 1 (green) compared with the (LPro9)-Kahalalide F (red).  Linear gradient of 
MeCN (+0.036% TFA) into H2O (+0.045% TFA), from 30% to 100% in 15 min.   
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Conclusions  
Here we developed several convergent strategies for the synthesis of the analogues of the antitumor peptide 
Kahalalide F. The best approaches were those in which the C-terminal amino acid of the C-Component is 
DPro because it avoids epimerization during the coupling of the fragment in solution. The choice of the semi-
permanent protecting group for the Nα-amino of Orn-protecting groups requires additional discussion.  Thus, 
the use of the less common groups, pNZ, and Alloc, which assure total stability of the lactone, implies the 
concourse of metallic cations or metals, which may demand a purification step before the final fragment 
coupling.  Furthermore, the Fmoc group requires fine-tuning of the experimental process, which can be 
detrimental for the development of a large scale process in which conditions may be more difficult to control.  
The use of the N-Component prepared by strategy 2 (Scheme 4) shows several advantages because it allows 
the preparation of Kahalalide F without risk of epimerization during cyclization and uses lower amounts of 
the precious Alloc-Phe-ZDhb-OH.   
Experimental Section 
General Procedures. Cl-TrtCl-resin, Protected Fmoc-amino acid derivatives, HOBt, HOAt were purchased 
from different sources as well as DIPEA, DIPCDI, EDC.HCl, piperidine, TFA, DMF, MeCN (HPLC grade) 
and CH2Cl2. All commercial reagents and solvents were used as received with the exception of DCM, which 
was passed through an alumina column to remove acidic contaminants. 
pNZ-Orn(Boc)-OH was prepared as described previously29 and Alloc-amino acids as essentially described 
by Dangles et al. and Cruz et al.37, 38  Alloc-ZDhb-Phe-OH was prepared as before39 
Solid-phase syntheses were performed in polypropylene syringes (10-50 mL), each fitted with a 
polyethylene porous disc. Solvents and soluble reagents were removed by suction.  The Fmoc group was 
removed with piperidine–DMF (2:8, v/v) (1 x 2 min, 2 x 10 min).  Washings between deprotection, coupling, 
and, again, deprotection steps were performed with DMF (5 x 0.5 min) and CH2Cl2 (5 x 0.5 min) using 10 
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mL solvent/g resin each time.  Peptide synthesis transformations and washings were done at 25 ºC.  
Syntheses carried out on solid-phase were controlled by HPLC of the intermediates obtained after cleaving an 
aliquot (approx. 2 mg) of the peptidyl-resin with TFA–H2O (1:99) for 1 min.  HPLC reversed-phase columns 
SymmetryTM C18 4,6 x 150 mm, 5 µm (column A) and Symmetry300TM C18 4,6 x 50 mm, 5 µm (column B) 
were used. Analytical HPLC was performed on an instrument comprising two solvent delivery pumps, 
automatic injector dual wavelength detector, and system controller (Breeze V3.20) and on an instrument 
comprising two solvent delivery pumps, automatic injector and a variable wavelength detector (Photodiode 
Array).  UV detection was at 215 or 220 nm, and linear gradients of MeCN (+0.036% TFA) into H2O 
(+0.045% TFA), from 30% to 100% in 15 min.   
MALDI-TOF and ES-MS analysis of peptide samples were performed  using ACH matrix,.  Peptide-resin 
samples for amino acid analysis were hydrolyzed in 12 N aqueous HCl-propionic acid (1:1), at 155 ºC for 1-3 
h and peptide-free samples were hydrolyzed in 6 N aqueous HCl at 155 ºC for 1 h.   
The “&” symbol is used in the nomenclature for cyclic peptides and precursors.40 The appearance of “&” in 
a given position of the one-line formula indicates the location of one end of a chemical bond and the second 
“&” the point to which this bond is attached. Thus, “&” represents the start or the end of a chemical bond, 
which is ‘cut’ with the aim to facilitate the view of a complex formula. In this way, two “&” symbols indicate 
one chemical bond. 
 
N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val&   from      
Fmoc-Orn(Boc)-OH: 
H-D-Val-O-TrtCl-resin (1): 
Cl-TrtCl-resin (1 g, 1.64 mmol/g) was placed in a 20 mL polypropylene syringe fitted with a polyethylene 
filter disk.  The resin was then washed with CH2Cl2 (5 x 0.5 min), and a solution of Fmoc-D-Val-OH (238 
mg, 0.7 mmol, 0.43 equiv) and DIPEA (0.41 mL) in CH2Cl2 (2.5 mL) was added. The mixture was then 
stirred for 15 min. Extra DIPEA (0.81 mL, total 7 mmol) was added and the mixture was stirred for an 
additional 45 min.  The reaction was stopped by adding  MeOH (800 µL) and stirring for 10 min.  The 
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Fmoc-D-Val-O-TrtCl-resin was subjected to the following washings/treatments with CH2Cl2 (3 x 0.5 min), 
DMF (3 x 0.5 min), piperidine as indicated in General Procedures, and DMF (5 x 0.5 min).  The loading was 
0.50 mmol/g, as calculated by Fmoc determination. 
 
[Fmoc-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-O-TrtCl-resin][Alloc-Val&] (2): 
Fmoc-D-allo-Ile-OH (707 mg, 2 mmol, 4 equiv), Fmoc-D-allo-Thr-OH (free hydroxy group) (683 mg, 2 
mmol, 4 equiv), and Fmoc-D-allo-Ile-OH (707 mg, 2 mmol, 4 equiv) were added sequentially to the above 
obtained H-D-Val-O-TrtCl-resin (1) using DIPCDI (310 µL, 2 mmol, 4 equiv) and HOBt (307 mg, 2 mmol, 4 
equiv) in DMF (2.5 mL).  In all cases, after 90 min of coupling, the ninhydrin test was negative.  Removal of 
Fmoc group and washings were performed as described in General Procedures.  Alloc-Val-OH (502 mg, 2.5 
mmol, 5 equiv) was coupled with DIPCDI (387 mg, 2.5 mmol, 5 equiv) in the presence of DMAP (30.6 mg, 
0.25 mmol, 0.5 equiv) and DIPEA (88 µL, 0.5 mmol, 1 equiv) for 45 min.  This coupling was repeated twice 
in the same conditions.  An aliquot of the peptidyl-resin was treated with TFA and the HPLC (Rt 14.2 min, 
column A) of the crude obtained after evaporation showed a purity of > 98%. ESMS, calcd. for C45H63N5O11, 
849.45.  Found: m/z 850.1 [M+H]+, 871.9 [M+Na]+. 
 
[Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-O-TrtCl-resin][Alloc-Val&] (3): 
The Fmoc group of the peptide resin (2) was removed and Fmoc-Orn(Boc)-OH (912 mg, 2 mmol, 4 equiv) 
was added using DIPCDI (310 µL, for 2.0 mmol and 4 equiv; and 388 µL, for 2.5 mmol and 5 equiv) and 
HOBt (307 mg, for 2.0 mmol and 4 equiv; and 395 mg, for 2.5 mmol and 5 equiv) for 90 min.  Ninhydrin test 
after the incorporation was negative.  An aliquot of the peptidyl-resin was treated with TFA and the HPLC 
(Rt 12.8 min, column A) of the crude obtained after evaporation showed a purity of 90 %. ESMS, calcd. for 
C56H81N7O14, 1,063.58.  Found: m/z 1,086.77 [M+Na+]+.  
 
[Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-O-TrtCl-resin][Alloc-Phe-ZDhb-Val&] (4): 
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The Alloc group of the peptide resin (3) was removed with Pd(PPh3)4 (58 mg, 0.05 mmol, 0.1 equiv) in the 
presence of PhSiH3 (617 µL, 5 mmol, 10 equiv), followed by washings with diethyldithiocarbamate 0.02 M 
(3 x 15 min). Alloc-Phe-ZDhb-OH (666 mg, 2 mmol, 4 equiv) and HOAt (273 mg, 2 mmol, 4 equiv) were 
dissolved in DMF (1.25 mL) and added to peptidyl-resin. DIPCDI (310 µL, 2 mmol, 4 equiv) was then added 
and the mixture was stirred for 5 h. The ninhydrin test was negative.  After washings with DMF and CH2Cl2, 
an aliquot of the peptidyl-resin was treated with TFA–H2O (1:99) for 1 min and the product was 
characterized by MALDI-TOF-MS: calcd. for C68H95N9O16, 1,293.69 Found: m/z 1,294.35 [M+H]+, 1,316.39  
[M+Na]+, 1,333.34 [M+K]+. 
 
[Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-OH][H-Phe-ZDhb-Val&] (5): 
The Alloc group of the peptide resin (4) was removed with Pd(PPh3)4 (58 mg, 0.05 mmol, 0.1 equiv) in the 
presence of PhSiH3 (617 µL, 5 mmol, 10 equiv), the resin was washed with sodium diethyldithiocarbamate in 
DMF 0.02 M (3 x 15 min) and the protected peptide was cleaved from the resin by TFA–CH2Cl2 (1:99) (5 x 
30 sec).  The filtrate was collected on H2O (4 mL) and the H2O was partially removed under reduced 
pressure.  MeCN was then added to dissolve solid that formed during the removal of H2O, and the solution 
was lyophilized to give 700 mg of title compound (578 µmol, 99% yield) of the title compound with a purity 
of > 91 % as checked by HPLC (Column A, Rt 8.59 min)], which was used without further purification.  
MALDI-TOF-MS, calcd. for C64H91N9O14, 1,209.67.  Found: m/z 1,210.45 [M+H]+, 1,232.51  [M+Na]+, 
1,248.45 [M+K]+. 
 
Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (6): 
The protected peptide (5) was dissolved in CH2Cl2 (580 mL, 1 mM), and HOBt (137 mg, 2.3 mmol) 
dissolved in the minimum volume of DMF to dissolve HOBt, DIPEA (302 µL, 1.73 mmol, 3 equiv), and 
DIPCDI (356 µL, 2.3 mmol, 4 equiv) were added.  The mixture was stirred for 1 h, and the course of the 
cyclization step was then checked by HPLC (column A, Rt 12.4 min).  The solvent was removed by 
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evaporation under reduced pressure and the product was used without further purification.  MALDI-TOF-
MS, calcd. for C64H89N9O13, 1,191.66.  Found: m/z 1,092.17 [M+H]+, 1,214.14 [M+Na]+, 1,230.10 [M+K]+.  
 
H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1): 
The protected peptide (6) (50 mg, 42 µmol) was dissolved in DMF (5 mL), then DEA (130 µL, 30 equiv) 
was added and the mixture was stirred for 90 min.  The solvent was removed by evaporation under reduced 
pressure.  The crude product was purified by HPLC (Symmetry C8 5 µm, 30 x 100 mm), linear gradient of 
MeCN (30% to 75% in 15 min) MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 
nm.  The product was characterized by HPLC (Rt 8.7 min, Condition A) and MALDI-TOF-MS, calcd. 
C49H79N9O11, 969.59.  Found: m/z  970.87 [M+H]+, 870.78 [M-Boc]+.  
 
N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& from pNZ-
Orn(Boc)-OH: 
pNZ-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (7): 
The synthesis was performed in the same way as for compound 6, but Fmoc-Orn(Boc)-OH was replaced by 
pNZ-Orn(Boc)-OH. 
H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1) 
The protected peptide (14.7 mg, 12.8 µmol) was dissolved in 1.6mM HCl in DMF (10 mL), SnCl2  (3,8 g, 
20mmol) was then added and the mixture was stirred
 
until HPLC (Column A) showed the completion of the 
reaction (1h).  The solvent was removed by evaporation under reduced pressure.  The crude product was 
purified by HPLC (Symmetry C8 5 µm, 30 x 100 mm), gradient of MeCN (30% to 75% in 15 min) MeCN 
(+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title product (4.8 mg, 4.9 
µmol, 40 % yield).  The product was characterized by HPLC (Rt 8.2 min, Column A) and for MALDI-TOF-
MS: calcd. C49H79N9O11, 969.59.  Found: m/z  992.35 [M+Na]+, 870.34 [M-Boc]+, 892.34 [M+Na-Boc]+.  
 
N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& from  
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Alloc-Orn(Boc)-OH: 
H-Phe-ZDhb-O-TrtCl-resin (8): 
 Cl-TrtCl-resin (1 g, 1.64 mmol/g) was placed in a 20 mL polypropylene syringe fitted with a 
polyethylene filter disk.  The resin was then washed with CH2Cl2 (5 x 0.5 min) and a solution of Alloc-Phe-
ZDhb-OH (232 mg, 0.7 mmol, 0.42 equiv) and DIPEA (0.41 mL) in CH2Cl2 (2.5 mL) was added. This 
mixture was then stirred for 15 min. Extra DIPEA (0.81 mL, total 7 mmol) was added and the mixture was 
stirred for an additional 45 min.  The reaction was arrested by adding MeOH (800 µL), after stirring for 10 
min.  The Alloc-Phe-ZDhb-O-TrtCl-resin was subjected to the following washings with CH2Cl2 (3 x 0.5 
min), DMF (3 x 0.5 min), and the Alloc group was removed with Pd(PPh3)4 (58 mg, 0.05 mmol, 0.1 equiv) in 
the presence of PhSiH3 (617 µL, 5 mmol, 10 equiv) in CH2Cl2.  The resin was washed as described in 
General Procedures.  The loading was 0.68 mmol/g, as calculated by Fmoc determination. 
 
[Alloc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-OH][H-Val&] (9): 
Fmoc-D-Val-OH (678 mg, 2 mmol, 4 equiv), Fmoc-D-allo-Ile-OH (707 mg, 2 mmol, 4 equiv), Fmoc-D-
allo-Thr-OH (free hydroxy group) (683 mg, 2 mmol, 4 equiv), Fmoc-D-allo-Ile-OH (707 mg, 2 mmol, 4 
equiv), and Alloc-Orn(Boc)-OH (630 mg, 2 mmol, 4 equiv) were added sequentially to the above obtained H-
Phe-ZDhb-O-TrtCl-resin (8) using DIPCDI (310 µL, 2 mmol, 4 equiv) and HOBt (307 mg, 2 mmol, 4 equiv) 
in DMF (2.5 mL).  In all cases, after 90 min of coupling, the ninhydrin test was negative.  Removal of Fmoc 
group and washings were performed as described in General Procedures.  Fmoc-Val-OH (848.2 mg, 2.5 
mmol, 5 equiv) was coupled with DIPCDI (387 mg, 2.5 mmol, 5 equiv) in the presence of DMAP (30.6 mg, 
0.25 mmol, 0.5 equiv) and DIPEA (88 µL, 0.5 mmol, 1 equiv) for 45 min.  This coupling was repeated twice 
in the same conditions.  After removal of the Fmoc group as described in General Procedures, the protected 
peptide was cleaved from the resin by TFA–CH2Cl2 (1:99) (5 x 30 sec).  Filtrate was collected on H2O (4 
mL) and the H2O was partially removed under reduced pressure.  MeCN was then added to dissolve the solid 
that formed during H2O removal, and the solution was lyophilized to give 650 mg of target compound (606 
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µmol, 90 % yield) of the title compound with a purity of > 75 % as checked by HPLC (Column A, Rt 9.93 
min).  ESMS, calcd. for C53H85N9O14, 1072,29.  Found: m/z 1074,4 [M+H]+.  
 
Alloc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (10): 
Peptide 9 (250 mg, 233 µmol) was dissolved in CH2Cl2 (240 mL, 1 mM), and HOAt (126 mg, 9.325 mmol, 
4 equiv) in the minimum volume of DMF, and DIPCDI (143 µL, 9,325 mmol, 4 equiv) were added.  The 
mixture was stirred for 24 h and the course of the cyclization step was then checked by HPLC (column A, Rt 
12.82 min).  The solvent was removed by evaporation under reduced pressure and the product was used 
without further purification. MALDI-TOF-MS, calcd. for C53H83N9O13, 1,054.28.  Found: m/z 1,056.4 
[M+H]+.  
 
H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1): 
Peptide 10 was dissolved in 10 mL of CH2Cl2, then Pd(PPh3)4 (8 mg, 6,94 µmol, 0.03 equiv) in the 
presence of PhSiH3 (94 µL, 763,6 µmol, 3.3 equiv) was added and the mixture was stirred for 90 min.  The 
solvent was removed by evaporation under reduced pressure.  The crude product was purified by HPLC 
(Symmetry C8 5 µm, 30 x 100 mm), linear gradient of MeCN (20% to 80% in 15 min) MeCN (+0.05% TFA) 
in water (+0.05% TFA), 20 mL/h, detection at 220 nm.  The product was characterized by HPLC (Rt 9.19 
min, Condition A) and for MALDI-TOF-MS, calcd. C49H79N9O11, 970.21.  Found: m/z  972.1 [M+H]+.  
 
C-Component 1: MeHex-D-Val-Thr(tBu)-Val-D-Val-D-Pro-OH 
 Cl-TrtCl-resin (1 g, 1.64 mmol/g) was placed in a 20 mL polypropylene syringe fitted with a 
polyethylene filter disk.  The resin was then washed with CH2Cl2 (5 x 0.5 min), a solution of Fmoc-D-Pro-
OH (237 mg, 0.7 mmol, 0.43 equiv) and DIPEA (0.41 mL) in CH2Cl2 (2.5 mL) was added, and the mixture 
was stirred for 15 min. Extra DIPEA (0.81 mL, total 7 mmol) was added and the mixture was stirred for an 
additional 45 min.  The reaction was arrested by stirring the resin in MeOH (800 µL)  for 10 min. The 
Fmoc-D-Pro-O-TrtCl-resin was subjected to the following washings/treatments with CH2Cl2 (3 x 0.5 min), 
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DMF (3 x 0.5 min), piperidine as indicated in General Procedures, and DMF (5 x 0.5 min).  The loading was 
0.27 mmol/g, as calculated by Fmoc determination. 
Fmoc-D-Val-OH (458 mg, 1.32 mmol, 5 equiv), Fmoc-Val-OH (360 mg, 1.06 mmol, 4 equiv), Fmoc-
Thr(tBu)-OH (527 mg, 1.32 mmol, 5 equiv), Fmoc-D-Val-OH (360 mg, 1.06 mmol, 4 equiv), and MeHex-
OH (138 mg, 1.06 mmol, 4 equiv) were added sequentially to the above peptide resin using DIPCDI (165 µL, 
for 1.06 mmol and 4 equiv; and 205 µL, for 1.32 mmol and 5 equiv) and HOBt (162 mg, for 1.06 mmol and 
4 equiv; and 203 mg, for 1.32 mmol and 5 equiv) for 90 min.  In all cases, after 90 min of coupling, the 
ninhydrin test was negative.  Removal of Fmoc group and washings were performed as described in General 
Procedures. 
The partially protected peptide was cleaved from the resin by TFA–CH2Cl2 (1:99) (5 x 30 sec).  Filtrate 
was collected on H2O (4 mL) and H2O was partially removed in a rotavapor.  MeCN was then added to 
dissolve the solid that formed during H2O removal, and the solution was lyophilized to give 154.4 mg (226 
µmol, 86 % yield) of the title compound with a purity of > 94 % as checked by HPLC (Column A, Rt 12.13 
min).  The crude obtained after evaporation showed a purity of > 94 %.  The product was characterized by 
ES-MS. Calcd. for C35H63N5O8, 681.9.  Found: m/z  682.15. 
Kahalalide F: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-
Phe-ZDhb-Val& from C- and N-Components 1  
N-Component 1 (8.25 mg, 8.5 µmol) and C-Component 1 (7 mg, 10.2 µmol, 1.2 equiv) were dissolved in 
DMF (10 mL) and PyAOP (5.32 mg, 10.2 µmol, 1.2 equiv) and DIPEA (5.3 µl, 30.6 µmol, 3.6 equiv) were 
added at room temperature.  The mixture was stirred for 1 h, when extra PyAOP (5.32 mg, 10.2 µmol, 1.2 
equiv) was added.  The mixture was allowed to react for 2 h at room temperature until HPLC (Column A) 
showed completion of the reaction.  HPLC showed that the crude obtained after evaporation had a purity of > 
75 %. 
The crude product was purified by HPLC (Symmetry C8 5 µm, 30x 100 mm), linear gradient of MeCN 
(+0.05% TFA) in water (+0.05% TFA) (30% to 100% in 15 min), 20 mL/h, detection at 220 nm, to give the 
protected Kahalalide F (6.9 mg, 4.2 µmol, 49% yield). 
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MALDI-TOF-MS, calcd. for C84H140N14O18, 1,633.05.  Found: m/z   1,534.33 [M-Boc]+,1,556.26 [M-Boc+ 
Na]+  1,656.33 [M+Na]+.  
Protected Kahalalide F was dissolved in TFA–H2O (19:1, 700 µL) and the mixture was stirred for 1 h.  The 
solvent was removed by evaporation under reduced pressure and dioxane was added (245 µL). Again, the 
solvent was removed by evaporation under reduced pressure (the process was repeated three times), H2O (1 
mL) was then added and the solution was lyophilized.  The crude product was purified by HPLC (Symmetry 
C8 5 µm, 30 x 100 mm), isocratic 44% MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 
220 nm, to give the title product (5 mg, 3.4 µmol, 80 % yield, 93.3%).   
The HPLC of the crude product did not show the epimeric peptide MeHex-D-Val-Thr-Val-D-Val-Pro-Orn-
D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (Epimer 1). This observation indicates 
racemization during the coupling step between the two protected peptides.  MALDI-TOF-MS, calcd. for 
C75H124N14O16, 1,476.93.  Found: m/z 1,478.17 [M+H]+ 1,500.14 [M+Na]+, 1,516.12 [M+K]+. 
 
Epimer 1: MeHex-D-Val-Thr-Val-D-Val-Pro-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-
ZDhb-Val& 
Experimental procedures were as described for the stepwise synthesis of Kahalalide F, except that Fmoc-D-
Pro-OH was replaced by Fmoc-Pro-OH.8  The product was characterized by HPLC (Rt 11.23 min, Column A) 
and for MALDI-TOF-MS: calcd. C75H124N14O16, 1,476.93.  Found: m/z 1,500.23 [M+Na]+, 1,515.97 
[M+K]+. 
 
N-Component 2: H-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& 
Starting with [Fmoc-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-O-TrtCl-resin][Alloc-Val&] (2), the Alloc 
group was removed with Pd(PPh3)4 (58 mg, 0.05 mmol, 0.1 equiv) in the presence of PhSiH3 (617 µL, 5 
mmol, 10 equiv) and the resin was washed with sodium diethyldithiocarbamate in DMF 0.02 M (3 x 15 min). 
Alloc-Phe-ZDhb-OH (666 mg, 2 mmol, 4 equiv) and HOAt (273 mg, 2 mmol, 4 equiv) were dissolved in 
DMF (1.25 mL) and added to peptidyl-resin. DIPCDI (310 µL, 2 mmol, 4 equiv) was then added and the 
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mixture was stirred for 5 h; at which point the HPLC showed completion of reaction (Rt 7.09 min, Column 
A). 
The Fmoc group was removed and after extensive DMF washings, Boc2O (546 mg, 5 equiv) and DIPEA 
(0.87 mL, 10 equiv) in DMF were added and left to react for 2 h. The ninhydrin test was negative at this time 
point.*  After DMF washings, the Alloc group was removed and the protected peptide was cleaved from the 
resin with TFA–CH2Cl2 (1:99) (5 x 30 sec).  Filtrate was collected on H2O (4 mL) and H2O was partially 
removed under reduced pressure.  MeCN was then added to dissolve the solid that formed during H2O 
removal and the solution was then lyophilized.    
Cyclization was performed as for compound 6 and Boc was then removed with TFA–H2O (19:1) (1 h).  
The solvent was removed under reduced pressure and dioxane was added (245 µL). Again, the solvent was 
removed by evaporation under reduced pressure (the process was repeated three times), and then H2O (1mL) 
was added and lyophilized.  The crude product was purified by HPLC (Symmetry C8 5 µm, 30 x 100 mm), 
isocratic 44% MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title 
product (207 mg, 273 µmol, 55  % yield, 93.3%). The product was characterized by HPLC (Rt 7.27 min, 
Column A) and for MALDI-TOF-MS: calcd. C39H61N7O8, 755.46.  Found: m/z 756.56 [M+H]+, 778.55 
[M+Na]+, 794.53 [M+K]+. 
 
C-Component 2: MeHex-D-Val-Thr(tBu)-Val-D-Val-D-Pro-Orn(Boc)-OH 
Experimental procedures as for C-Component 1, except that the peptide synthesis was initiated by 
incorporation of Fmoc-Orn(Boc)-OH to the Cl-TrtCl-resin.  The product was characterized by HPLC (Rt 
13.27 min, Column A) and for Electrospray. Calcd  C45H81N7O11, 895,60.  Found: m/z 895,10 . 
 
Kahalalide F: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-
Phe-ZDhb-Val& from C- and N-Components 2 
                                                 
*
 Alternatively, Boc-D-allo-Ile-OH can be introduced instead of the Fmoc derivative.  
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The synthesis was performed as described above except that the condensed fragments were N-Component 2 
and C-Component 2.   The HPLC of the crude final product showed the presence of the epimeric peptide 
MeHex-D-Val-Thr-Val-D-Val-D-Pro-D-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& 
(4.1%) (Epimer 2), which indicates racemization during the coupling step between both protected peptides.  
The product was characterized by HPLC (Rt 10.5 min, Column A).  MALDI-TOF-MS, calcd. C75H124N14O16, 
1,476.93. Found: m/z 1,477.99 [M+H]+ 1,499.97 [M+Na]+, 1,515.93 [M+K]+. 
 
Epimer 2: MeHex-D-Val-Thr-Val-D-Val-D-Pro-D-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-
Phe-ZDhb-Val& 
The synthesis was carried out as described for the stepwise synthesis of Kahalide except that Fmoc-
Orn(Boc)-OH is replaced by Fmoc-D-Orn(Boc)-OH.8  The product was characterized by HPLC (Rt 9.89 min, 
Column A).  MALDI-TOF-MS, calcd C75H124N14O16, 1,476.93. Found: m/z 1,478.06 [M+H]+ 1,500.15 
[M+Na]+, 1,516.04 [M+K]+. 
 
N-Component 3: H-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& 
Starting with Fmoc-D-allo-Thr-D-allo-Ile-D-Val-Phe-ZDhb-O-TrtCl-resin, the Fmoc group was removed 
and after extensive DMF washings, Boc2O (546 mg, 5 equiv) and DIPEA (0.87 mL, 10 equiv) in DMF were 
added and left to react for 2 h, after which the ninhydrin test was negative.  After DMF washings, Fmoc-Val-
OH (848.2 mg, 2.5 mmol, 5 equiv) was coupled with DIPCDI (387 µL, 2.5 mmol, 5 equiv) in the presence of 
DMAP (30.6 mg, 0.25 mmol, 0.5 equiv) and DIPEA (88 µL, 0.5 mmol, 1 equiv) for 45 min.  This coupling 
was repeated in the same conditions twice.  After removal of the Fmoc group as described in General 
Procedures, the protected peptide was cleaved from the resin by TFA–CH2Cl2 (1:99) (5 x 30 sec).  Filtrate 
was collected on H2O (4 mL) and the H2O was partially removed under reduced pressure.  MeCN was then 
added to dissolve the solid that appeared during the H2O removal, and the solution was lyophilized, to give 
57 mg (75 µmol, 90% yield) of the title compound with a purity of > 95 %, as checked by HPLC (Column A, 
Rt 7.95 min). ESMS, calcd. for C38H60N6O10, 760.44.  Found: m/z 762.3 [M+H]+. 
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Cyclization was carried out as for compound 6, and the Boc was then removed with TFA–H2O (19:1) (1 h).  
The solvent was removed under reduced pressure and dioxane was added (245 µL). The solvent was removed 
by evaporation under reduced pressure (the process was repeated three times), and then H2O (1mL) was 
added and lyophilized.  The crude product was purified by HPLC (Symmetry C8 5 µm, 30 x 100 mm), 
isocratic 30 % MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title 
product (50.2 mg, 67.6 µmol, 90  % yield). 
The product was characterized by HPLC (Rt 5.32 min, Column A) and for ES-MS, calcd. C33H61N6O9, 
642.37.  Found: m/z  642.035. 
C-Component 3: MeHex-D-Val-Thr(tBu)-Val-D-Val-D-Pro-Orn(Boc)-D-allo-Ile-OH 
Experimental procedures as for the obtention of C-Component 1, except that the peptide synthesis was 
initiated by incorporation of Fmoc-D-allo-Ile-OH to the Cl-TrtCl-resin.  The product was characterized by 
HPLC (Rt 10.25 min, Column A) and for MALDI-TOF-MS, calcd.  C51H92N8O12, 1,008.68.  Found: m/z 
1,009.8. 
 
Kahalalide F: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-
Phe-ZDhb-Val& from C- and N-Components 3 
Experimental procedures were as described for the other syntheses of Kahalalide F. The HPLC of the final 
product showed the presence of the epimeric peptide MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-Ile-D-allo-
Thr(&)-D-alloIle-D-Val-Phe-ZDhb-Val& (Epimer 3), which indicates racemization during the coupling step 
between the two protected peptides.  The product was characterized by HPLC (Rt 7.92 min, Column A).  
MALDI-TOF-MS, calcd. C75H124N14O16, 1,476.93. Found: m/z 1,478.5 [M+H]+ 1,501.4 [M+Na]+, 1,517.6 
[M+K]+. 
 
Epimer 3: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-
Val& 
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Experimental procedures were as described for the stepwise synthesis of Kahalaide F, except that Fmoc-Ile-
OH was used instead of Fmoc-D-allo-Ile-OH.8  MeHex-D-Val-Thr(tBu)-Val-D-Val-D-Pro-Orn(Boc)-Ile-OH: 
(Rt 10.25 min, Column A and MALDI-TOF-MS, calcd.  C51H92N8O12, 1,008.68.  Found: m/z 1,009.5).  The 
final product was characterized by HPLC (Rt 8.02 min, Column A).  MALDI-TOF-MS, calcd. 
C75H124N14O16, 1,476.93. Found: m/z 1,478.2 [M+H]+ 1,501.1 [M+Na]+, 1,517.3 [M+K]+. 
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